Rising triangle in anticipation of accelerated approval of FDAPharming has received acceptance from both the EMA and FDA for the accelerated review of leniolisib. The new drug is anticipated to generate significantly more revenue compared to its current profitable drug Ruconest. While the company has been profitable for the past years, it needed to find new so
